Hosted on MSN2d
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?
Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Fact-checking Warren's claim about RFK Jr.'s work on vaccine lawsuits
During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...
Hosted on MSN4d
GSK stays optimistic on vaccines amidst US and China woes
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
Merck Shares Hit After Guidance Falls Short, Gardasil Challenge
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Merck Earnings: Gardasil Weighs on 2025 Growth, but Firm Still Undervalued
Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck beats estimates on Q4 earnings, stock slides on tepid 2025 guidance
Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Merck stops Gardasil shipments to China, hitting 2025 outlook; shares tumble
Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...